Cure8 research brief
This report may be relevant to people with Crohn’s disease who also have alopecia areata because it describes hair regrowth after switching biologic therapy, suggesting a possible shared immune mechanism and a potential treatment consideration.
Patients with Crohn’s disease and coexisting alopecia areata; clinicians prescribing biologics; dermatologists and IBD researchers.
This is a single case report of an 18-year-old man with Crohn’s disease and coexisting alopecia areata whose hair loss resolved after switching from vedolizumab to ustekinumab.
Vedolizumab had controlled his intestinal disease but not the alopecia; after starting ustekinumab (IV induction then 90 mg SC every 8 weeks) the report describes marked regrowth by 24 weeks and complete resolution by 48 weeks while Crohn’s remained in remission.
The paper suggests that blocking IL-12/IL-23 with ustekinumab might help refractory alopecia areata in the context of Crohn’s disease, potentially when a shared immune pathway is suspected. However, this is a single-patient observation and cannot establish effectiveness or safety broadly.
If you are on or considering biologic therapy and have new or ongoing autoimmune skin disease, discuss the case with your gastroenterologist and dermatologist; treatment decisions should be individualized and guided by larger studies and specialist input.
Single-case evidence: helpful for hypothesis generation but not proof of efficacy. Treatment decisions require specialist discussion and higher-quality studies.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For people with Crohn's disease who no longer respond to single biologic agents, combining two different biologics (ustekinumab + vedolizumab) may recapture response and lower inflammation markers, offering a possible...
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
